Interfaces between cellular responses to DNA damage and cancer immunotherapy
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
The DNA damage response (DDR) fulfils essential roles to preserve genome integrity. Targeting the DDR in tumors has had remarkable success over the last decade, exemplified by the licensing of PARP inhibitors for cancer therapy. Recent studies suggest that the application of DDR inhibitors impacts on cellular innate and adaptive immune responses, wherein key DNA repair factors have roles in limiting chronic inflammatory signaling. Antitumor immunity plays an emerging part in cancer therapy, and extensive efforts have led to the development of immune checkpoint inhibitors overcoming immune suppressive signals in tumors. Here, we review the current understanding of the molecular mechanisms underlying DNA damage-triggered immune responses, including cytosolic DNA sensing via the cGAS/STING pathway. We highlight the implications of DDR components for therapeutic outcomes of immune checkpoint inhibitors or their use as biomarkers. Finally, we discuss the rationale for novel combinations of DDR inhibitors with antagonists of immune checkpoints and current hindrances limiting their broader therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 1×
“Increased mutational load is a promising indicator of ICB responsiveness, and indeed, patients harboring mutations in MMR genes and displaying MSI showed strong responsiveness to PD-1 antagonists (Rizvi et al. 2015; Le et al. 2017; Overman et al. 2017).”
BackgroundThe DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 1×
“Consequently, dysregulation and mutations in such DDR factors and their regulators have implications for human health and disease (Jackson and Bartek 2009).”
BackgroundSelf-citationSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368 · cited 1×
“This complex network of DNA damage sensor, mediator, and effector proteins is known as the DNA damage response (DDR) (Ciccia and Elledge 2010).”
BackgroundSTING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 2×
“…factor 3 (IRF3) and IκBα transduces the initial stimulusof cytosol- ic DNA into IRF3 and NFκB transcriptional programs, which control the balance between cellular survival and controlled cell death (Fitzgerald et al. 2003; Ishikawa and Barber 2008; Ishikawa et al. 2009; Tanaka andChen 2012).”
BackgroundDevelopment of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434 · cited 2×
“Furthermore, a phase I clinical trial revealedmajor tumor regression in a group of metastatic melanoma patients treated with radiotherapy and an anti-CTLA-4 antibody (Twyman-Saint Victor et al. 2015).”
BackgroundResultCD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · cited 1×
“Moreover CTLA-4 expression by Tregs is crucial for their immune suppressive functions, potently binding CD80/CD86 ligands on APCs and therefore preventing T-cell activation (Takahashi et al. 2000; Wing et al. 2008).”
BackgroundCTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182 · cited 2×
“…supplementation of cGAMP to induce the antitumor efficacy of radiotherapy, further supporting the idea that in response to radiotherapy, cGAS/STING is an initial sensor and signal transducer of antitumor immune responses (Burnette et al. 2011; Woo et al. 2014; Wu et al. 2014; Deng et al. 2014b).”
BackgroundSTING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834
cGAS surveillance of micronuclei links genome instability to innate immunity
Mackenzie, K. J., Carroll, P., Martin, C.-A., Murina, O., Fluteau, A., Simpson, D. J., Olova, N., Sutcliffe, H., Rainger, J. K., Leitch, A., et al. (2017) · Nature · doi:10.1038/nature23449 · Cited by 1,752 · cited 2×
“Importantly, micronuclei formation requires progression through mitosis following DNA-damage induction, wherein the dissolution and ensuing reformation of the nuclear membrane end up enclosing DNA fragments in a micronuclear envelope (Harding et al. 2017; Mackenzie et al. 2017).”
BackgroundCGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING.
Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Röhl, I., Hopfner, K.-P., Ludwig, J., & Hornung, V. (2013) · Nature · doi:10.1038/nature12306 · Cited by 1,695 · cited 2×
“…catalyzes the synthesis of cyclic GMP-AMP (cGAMP) from ATP and GTP, which subsequently acts as a messenger molecule for the adaptor protein STING (Ablasser et al. 2013; Sun et al. 2013;Wu et al. 2013b). cGAS binds double-stranded DNA (dsDNA) in a sequence-nonspecific manner through interaction…”
BackgroundImmune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625 · cited 1×
“These scenarios result in the inability of innate and adaptive immune cells to recognize and appropriately respond to oncogenic cells, therefore facilitating tumor progression (escape phase) (Vinay et al. 2015).”
BackgroundMitotic progression following DNA damage enables pattern recognition within micronuclei
Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308
Trex1 prevents cell-intrinsic initiation of autoimmunity
Stetson, D. B., Ko, J. S., Heidmann, T., & Medzhitov, R. (2008) · Cell · doi:10.1016/j.cell.2008.06.032 · Cited by 1,280 · cited 3×
“In line with these observations, inactivation of cGAS/STING abrogates type I IFN signaling in TREX1-deficient cells and rescues the embryonic lethality of Trex1 mice (Stetson et al. 2008; Ablasser et al. 2014; Gray et al. 2015).”
BackgroundUsing immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034 · cited 3×
“3; Llosa et al. 2015; Mlecnik et al. 2016).”
BackgroundRadiotherapy induces responses of lung cancer to CTLA-4 blockade
Formenti, S. C., Rudqvist, N.-P., Golden, E., Cooper, B., Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Friedman, K., Ferrari de Andrade, L., Wucherpfennig, K. W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0232-2 · Cited by 928 · cited 1×
“Increased IFN-β secretion and clonal expansion of tumor-derived T-cell receptors (TCRs) predicted responsiveness to this combination therapy (Formenti et al. 2018), thereby highlighting the potential of radiotherapy to induce type I IFN responses promoting innate antitumor immunogenicity.”
BackgroundAicardi–Goutières syndrome and the type I interferonopathies
Crow, Y. J., & Manel, N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3850 · Cited by 925 · cited 5×
“Notably, individuals with mutations in the RNase H2 complex, consisting of RNASEH2A, RNASEH2B, and RNASEH2C, show clinical pathologies that resemble those observed in TREX1 mutated patients, including aberrant type I IFN signaling alongwithAGS and systemic lupus erythematosus.”
BackgroundInfluentialSen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1020 · Cited by 902
Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
Prakash, R., Zhang, Y., Feng, W., & Jasin, M. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016600 · Cited by 869 · cited 1×
“The tumor suppressor BRCA2 has a pivotal role in HR-mediated repair and in the protection of stalled replication forks, while its absence is accompanied by genome instability and chromosome breakage (Prakash et al. 2015).”
BackgroundPantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
Härtlova, A., Erttmann, S. F., Raffi, F. A., Schmalz, A. M., Resch, U., Anugula, S., Lienenklaus, S., Nilsson, L. M., Kröger, A., Nilsson, J. A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.012 · Cited by 716 · cited 2×
“Furthermore, in the absence of ATM, ssDNA resulting from unrepaired DNA lesions accumulates in the cytoplasm and activates cGAS/STING-dependent type I IFN signaling (Härtlova et al. 2015).”
BackgroundPARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572 · cited 2×
“Intriguingly, this immune response is augmented upon BRCA deficiency, since Brca1-proficient mouse tumors showmitigated immunogenicity in response to PARP inhibitors as compared with Brca1 mutated ones (Ding et al. 2018; Pantelidou et al. 2019).”
BackgroundHirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
High speed of fork progression induces DNA replication stress and genomic instability
Maya-Mendoza, A., Moudry, P., Merchut-Maya, J. M., Lee, M., Strauss, R., & Bartek, J. (2018) · Nature · doi:10.1038/s41586-018-0261-5 · Cited by 514 · cited 2×
“…potential to initiate cGAS/STING-dependent type I IFNproduction inhumancancercells independent of their BRCA gene status (Shen et al. 2019), presumably due to the mitotic defects or increased replication stress caused by PARPi affecting replication fork speed (Maya-Mendoza et al. 2018; Slade 2019).”
BackgroundFuruta, T., Takemura, H., Liao, Z.-Y., Aune, G. J., Redon, C., Sedelnikova, O. A., Pilch, D. R., Rogakou, E. P., Celeste, A., Chen, H. T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300198200 · Cited by 449
Rice, G., Newman, W. G., Dean, J., Patrick, T., Parmar, R., Flintoff, K., Robins, P., Harvey, S., Hollis, T., O’Hara, A., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/513443 · Cited by 410 · cited 1×
“Mutations inTREX1 result in dysregulation of type I IFN production and are associated with the autoimmune disordersAicardi-Goutières syndrome (AGS) and familial chilblain lupus (Crow et al. 2006a; Rice et al. 2007).”
BackgroundThe tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans
Charles, K. A., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thompson, R. G., Kollias, G., Smyth, J. F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39065 · Cited by 338
Nuclear envelope assembly defects link mitotic errors to chromothripsis
Liu, S., Kwon, M., Mannino, M., Yang, N., Renda, F., Khodjakov, A., & Pellman, D. (2018) · Nature · doi:10.1038/s41586-018-0534-z · Cited by 314
Structural mechanism of cGAS inhibition by the nucleosome
Pathare, G. R., Decout, A., Glück, S., Cavadini, S., Makasheva, K., Hovius, R., Kempf, G., Weiss, J., Kozicka, Z., Guey, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2750-6 · Cited by 273
The molecular basis of tight nuclear tethering and inactivation of cGAS
Zhao, B., Xu, P., Rowlett, C. M., Jing, T., Shinde, O., Lei, Y., West, A. P., Liu, W. R., & Li, P. (2020) · Nature · doi:10.1038/s41586-020-2749-z · Cited by 261 · cited 1×
“…against selfDNA is reported to be overcome by the tethering of cGAS to the acid patch of nucleosomes via its DNA binding domains, thus blocking DNA binding and activity toward chromatinized DNA (Boyer et al. 2020; Kujirai et al. 2020;Michalski et al. 2020; Pathare et al. 2020; Zhao et al. 2020).”
Structural basis for sequestration and autoinhibition of cGAS by chromatin
Michalski, S., de Oliveira Mann, C. C., Stafford, C. A., Witte, G., Bartho, J., Lammens, K., Hornung, V., & Hopfner, K.-P. (2020) · Nature · doi:10.1038/s41586-020-2748-0 · Cited by 256
cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity
Wang, Z., Chen, J., Hu, J., Zhang, H., Xu, F., He, W., Wang, X., Li, M., Lu, W., Zeng, G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127471 · Cited by 253 · cited 1×
“For example, the topoisomerase II inhibitor teniposide induces STING-dependent type I IFN signaling and NF-κB activation in a mouse tumor model, with the consequent DC and T-cell activation promoting antitumor responses, including increased immune cell infiltration (Wang et al. 2019).”
BackgroundCytosolic DNA Sensing in Organismal Tumor Control
Vanpouille-Box, C., Demaria, S., Formenti, S. C., & Galluzzi, L. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.013 · Cited by 250
Ribonuclease H2 mutations induce a cGAS/STING‐dependent innate immune response
Mackenzie, K. J., Carroll, P., Lettice, L., Tarnauskaitė, Ž., Reddy, K., Dix, F., Revuelta, A., Abbondati, E., Rigby, R. E., Rabe, B., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201593339 · Cited by 248
Structural basis for the inhibition of cGAS by nucleosomes
Kujirai, T., Zierhut, C., Takizawa, Y., Kim, R., Negishi, L., Uruma, N., Hirai, S., Funabiki, H., & Kurumizaka, H. (2020) · Science · doi:10.1126/science.abd0237 · Cited by 243
Structural basis of nucleosome-dependent cGAS inhibition
Boyer, J. A., Spangler, C. J., Strauss, J. D., Cesmat, A. P., Liu, P., McGinty, R. K., & Zhang, Q. (2020) · Science · doi:10.1126/science.abd0609 · Cited by 238 · cited 2×
“…against selfDNA is reported to be overcome by the tethering of cGAS to the acid patch of nucleosomes via its DNA binding domains, thus blocking DNA binding and activity toward chromatinized DNA (Boyer et al. 2020; Kujirai et al. 2020;Michalski et al. 2020; Pathare et al. 2020; Zhao et al. 2020).”
BackgroundSheng, H., Huang, Y., Xiao, Y., Zhu, Z., Shen, M., Zhou, P., Guo, Z., Wang, J., Wang, H., Dai, W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000340 · Cited by 228
Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0056 · Cited by 220 · cited 1×
“Additionally, a proof-of-concept clinical study further confirmed immune activation in ovarian cancers treated with olaparib and the anti-PD-L1 antibody durvalumab regardless of theirBRCA status, highlighted by increased IFN-γ production and tumor-infiltrating lymphocytes (Lampert et al. 2020).”
BackgroundVendetti, F. P., Karukonda, P., Clump, D. A., Teo, T., Lalonde, R., Nugent, K., Ballew, M., Kiesel, B. F., Beumer, J. H., Sarkar, S. N., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96519 · Cited by 198 · cited 2×
“Thus, combinatorial treatment of radiotherapy and ATR inhibition was found to induce type I/II IFN-based gene expression changes and CD8 T-cell infiltration in a manner dependent on cGAS/STING (Vendetti et al. 2018; Dillon et al. 2019; Sheng et al. 2020).”
BackgroundPARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
Kim, C., Wang, X.-D., & Yu, Y. (2020) · eLife · doi:10.7554/elife.60637 · Cited by 136
Cited by
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85
Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063238 · Cited by 42
“These IFN-induced immune responses are crucial for the killing of cancer cells; thus, IFN response induced by DDR targeting (PARPness) can enhance the efficacy of cancer immunotherapy [80,81].”
BackgroundZou, T., Liu, J.-Y., Qin, Q., Guo, J., Zhou, W.-Z., Li, X.-P., Zhou, H.-H., Chen, J., & Liu, Z.-Q. (2023) · Biomedicines · doi:10.3390/biomedicines11123133 · Cited by 10
Metadata
- Authors
- Pilger, D., Seymour, L. W., & Jackson, S. P.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2021-04-22
- Volume
- 35
- Issue
- 9-10
- Pages
- 602-618
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W6887896603
- Cited by
- 95
- References
- 55
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.